Sugi Predict

Sugi Predict / Compounds / SCHEMBL825278

SCHEMBL825278

SCHEMBL825278

CCCCCCCCCCCCCCCC(=O)O[C@@H](COP(=O)([O-])OCC[N+](C)(C)C)C(O)C(=O)CCCCCCCCCCCCC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.67
▸ NR5A2 O00482 1/20 0.67
▸ NR5A1 Q13285 1/20 0.67
▸ RECQL P46063 1/20 0.63
▸ MAPT P10636 3/20 0.62
▸ PLA2G1B P04054 1/20 0.56
▸ PLA2G2A P14555 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.55
▸ ADRA1D P25100 1/20 0.55
▸ PTAFR P25105 1/20 0.55
▸ HTR1D P28221 1/20 0.55
▸ HTR2C P28335 1/20 0.55
▸ ADRA1B P35368 1/20 0.55
▸ DRD3 P35462 1/20 0.55
▸ TMEM97 Q5BJF2 1/20 0.55
▸ PLA2G10 O15496 1/20 0.54
▸ MAPK1 P28482 4/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ GMNN O75496 2/20 0.53
▸ LMNA P02545 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30986129 1.00 SMN1; SMN2 (0.67) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL17065552 1.00 SMN1; SMN2 (0.67) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3861371 0.94 ALDH1A1 (0.65) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3867322 0.94 ALDH1A1 (0.65) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL6912576 0.94 SMN1; SMN2 (0.61) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL6027169 0.92 ALDH1A1 (0.69) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL2291835 0.86 SMN1; SMN2 (0.66) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL17962981 0.85 SMN1; SMN2 (0.61) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL9710185 0.85 SMN1; SMN2 (0.61) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL18210636 0.85 SMN1; SMN2 (0.61) SMN1; SMN2NR5A2NR5A1RECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4009950-A1 PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS Tesorx Pharma, LLC (US) 2022-06-15 — — EP claimed
WO-2021030260-A1 PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS TESORX PHARMA, LLC (US) 2021-02-18 — — WO claimed
EP-3233204-A2 COMPOSITION FOR ENHANCING HAIR FIBER PROPERTIES The Procter & Gamble Company (US) 2017-10-25 — — EP claimed
WO-2016100634-A2 COMPOSITION FOR ENHANCING HAIR FIBER PROPERTIES THE PROCTER & GAMBLE COMPANY (US) 2016-06-23 — — WO claimed
US-20240190921-A1 COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2024-06-13 — — US disclosed
WO-2024107474-A1 CONTROLLED LIPID SELF-ASSEMBLY FOR SCALABLE MANUFACTURING OF NEXT-GENERATION IMMUNE STIMULATING COMPLEXES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-05-23 — — WO disclosed
WO-2024054372-A1 MULITIVALENCY FOR ENZYME INHIBITION INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2024-03-14 — — WO disclosed
EP-4333874-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS Camurus AB (SE) 2024-03-13 — — EP disclosed
EP-4308105-A1 COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE Trained Therapeutix Discovery, Inc. (US) 2024-01-24 — — EP disclosed
WO-2023192956-A2 SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-10-05 — — WO disclosed
EP-4231999-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS Poseida Therapeutics, Inc. (US) 2023-08-30 — — EP disclosed
WO-2023141576-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS POSEIDA THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed
WO-2016022547-A1 TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-02-11 — — WO disclosed
WO-2015134892-A1 REMEDIATION OF ORGANIC TOXINS WITH LIPID BILAYER NANOPARTICLES TEMPLE UNIVERSITY-OF THE COMMONWELATH SYSTEM OF HIGHER EDUCATION (US) 2015-09-11 — — WO disclosed
EP-2672978-A1 PERMEATION ENHANCERS FOR TOPICAL FORMULATIONS Professional Compounding Centers Of America, Ltd. (US) 2013-12-18 — — EP disclosed
EP-2588157-A1 LIPID COATING FOR MEDICAL DEVICES DELIVERING BIOACTIVE AGENT SurModics, Inc. (US) 2013-05-08 — — EP disclosed
WO-2012109152-A1 PERMEATION ENHANCERS FOR TOPICAL FORMULATIONS PROFESSIONAL COMPOUNDING CENTERS OF AMERICA, LTD. (US) 2012-08-16 — — WO disclosed
WO-2012109151-A1 PERMEATION ENHANCERS WITH LIPOSOMES FOR TOPICAL FORMULATIONS PROFESSIONAL COMPOUNDING CENTERS OF AMERICA, LTD. (US) 2012-08-16 — — WO disclosed
WO-2012097049-A2 DNA REPAIR ENZYME INHIBITOR NANOPARTICLES AND USES THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2012-07-19 — — WO disclosed
WO-2012003293-A1 LIPID COATING FOR MEDICAL DEVICES DELIVERING BIOACTIVE AGENT SURMODICS, INC. (US) 2012-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190921-A1 COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE MYD88, CD74, IRF3 SMN1; SMN2 4751/4885NR5A2 446/4885NR5A1 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.